Trial Profile
A prospective randomised controlled trial assessing the efficacy of Pegatanib sodium (Macugen) in the prevention of proliferative diabetic retinopathy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms EPPPDR
- 14 Jul 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2007-006795-10).
- 02 Jan 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 03 May 2010 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.